Month: October 2022
-
“Dark Genome” Drug Discoverer Gains $37M in Early Funds
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University of Oxford medical school. Nucleome Therapeutics is seeking new treatments for…
-
Guide to Entering and Profiting in the World of Investments
By investing in a company, product, or venture, you are essentially betting that the future will be brighter than the present.
-
Trial Shows Wearable Device Can Reduce Migraine
Results from a clinical trial show an electronic device worn on the arm can reduce migraine occurrences in people with history of the condition.
-
Three Tips for Starting as a Freelance Consultant
What does it take to be an effective freelance consultant?
-
Tech Maintenance
Science & Enterprise’s parent company is undergoing a technology upgrade, so we won’t be publishing today.
-
Infographic – US Biotech Venture Funds Fall in Q3
Venture funds for U.S. biotechnology and pharmaceutical start-ups declined in the third quarter of 2022 from the 2021 record pace, but remain on track for historic highs.
-
Trial Begins Testing RNA Hepatitis-B Treatment
A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease.
-
Hydrogel Biomaterials Company Raises $3M in Early Funds
A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round.
-
Start-Up to Manufacture, Supply Practical Radiation Drugs
A new company formed by a technology venture investor and the Mayo Clinic aims to produce and supply more readily available radiation drug therapies.
-
Gene Therapy Stimulates Missing Enzymes in Rare Disease
Results from a clinical trial show an experimental gene therapy for Krabbe disease is safe and produces enzymes missing in children with the rare disease.